Characterization of the Performance of Bin Blenders Part 1 of 3: Methodology

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-02-2004
Volume 28
Issue 5

Bin blender performance is comprehensively reviewed using both free-flowing and cohesive mixtures.

External Link - article-94550.pdf

Articles in this issue
i18_t-143862-1408695846297.jpg
Characterization of the Performance of Bin Blenders Part 1 of 3: Methodology
An LC Method for the Separation and Determination of Ethynodiol Diacetate and Ethinyl Estradiol in Tablets
In The Spotlight-May 2004
FDA Eyes Manufacturing Innovation to Boost Drug Development
Prepare for Bar Coding
Validation and Compliance: Software Systems Prepare Manufacturers for Com(PAT)ibility
aaiPharma Situation Underscores The Need for Due Diligence
Excipient Functionality
Characterization of the Performance of Bin Blenders Part 1 of 3: Methodology
May 2004
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Roger Viney, PhD, chief commercial officer for ICE Pharma
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

ACG to Showcase Sustainability Innovations at Pharmapack Europe 2025

Susan Haigney
January 21st 2025
Article

The company will be featuring its sustainable packaging solutions at the event in Paris on Jan. 22–23, 2025.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Samsung Biologics Scores Major Manufacturing Deal Worth Over $1.4 Billion with European Pharma Company

Feliza Mirasol
January 17th 2025
Article

Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

PackGene and GC4K Team Up Along with Weill Cornell Medicine for Gene Therapy to Treat Rare Neurological Disease

Feliza Mirasol
January 11th 2025
Article

Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

J&J Gets FDA Fast Track Designation for Alzheimer’s mAb, Posdinemab

Feliza Mirasol
January 9th 2025
Article

Posdinemab is the second tau-directed investigational therapy by J&J that has received fast track designation from FDA this year for Alzheimer’s disease.